Southpoint Capital Advisors LP Has $157.23 Million Position in Becton, Dickinson and Company $BDX

Southpoint Capital Advisors LP cut its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 28.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,000,000 shares of the medical instruments supplier’s stock after selling 400,000 shares during the quarter. Becton, Dickinson and Company accounts for about 3.2% of Southpoint Capital Advisors LP’s portfolio, making the stock its 14th biggest holding. Southpoint Capital Advisors LP’s holdings in Becton, Dickinson and Company were worth $157,230,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC boosted its position in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of Becton, Dickinson and Company by 20.4% in the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after purchasing an additional 1,354 shares during the last quarter. United Bank lifted its position in shares of Becton, Dickinson and Company by 23.9% in the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after purchasing an additional 993 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Becton, Dickinson and Company by 365.1% in the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after purchasing an additional 25,022 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in Becton, Dickinson and Company by 34.7% during the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after purchasing an additional 6,058 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $158.94 on Tuesday. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. The firm’s 50-day simple moving average is $150.29 and its 200 day simple moving average is $164.40. The firm has a market cap of $43.80 billion, a price-to-earnings ratio of 40.24, a P/E/G ratio of 11.06 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. During the same quarter in the previous year, the firm posted $3.35 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 12.62 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. The trade was a 7.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,114 shares of company stock worth $753,877 in the last three months. 0.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BDX. Piper Sandler lowered their price target on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Evercore set a $180.00 target price on Becton, Dickinson and Company in a report on Monday, July 6th. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Weiss Ratings cut Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Finally, Wells Fargo & Company raised their target price on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $180.29.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.